Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Common Equity (2024 - 2025)

Historic Common Equity for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to $68.8 million.

  • Pyxis Oncology's Common Equity fell 5524.53% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 5524.53%. This contributed to the annual value of $120.8 million for FY2024, which is N/A changed from last year.
  • Pyxis Oncology's Common Equity amounted to $68.8 million in Q3 2025, which was down 5524.53% from $87.6 million recorded in Q2 2025.
  • Pyxis Oncology's Common Equity's 5-year high stood at $184.2 million during Q1 2024, with a 5-year trough of $68.8 million in Q3 2025.